Memantine for Epileptic Encephalopathy

• Status: Recruiting
• Trial end date: 2022-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the potential benefit of memantine hydrochloride as treatment for children with epileptic encephalopathy using a double-blind placebo-controlled cross-over design.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kenneth Myers, MD
• Treatments: Memantine

Criteria

Inclusion Criteria:

• Written informed consent obtained

• Age 6-18 years (Weight ≥ 20 kg)

• Clinical diagnosis of epileptic encephalopathy

• Subject with epilepsy and developmental impairment;

• Epileptic activity itself contributes to severe cognitive and behavioural impairments

• Patients will typically have already have trialed at least two standard therapies

• Females of childbearing age:

• Negative urinary pregnancy test at screening

• Agree to use effective contraception for the duration of the study

Exclusion Criteria:

• Inability of a parent or legal guardian to give informed consent for any reason.

• Known hypersensitivity to memantine hydrochloride

• Taking concomitant Amantadine, Ketamine or Dextromethorphan, Cimetidine, Ranitidine, Procainamide, Quinidine, Quinine, Hydrochlorothiazide, Anticholinergics, L-dopa, Anticoagulant,

• Any degree of renal impairment